News Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
May 9, 2017
- Sierra ends Q1 with $125M to fund current operating plans through approximately mid-2019 - - Amendments to ongoing Phase 1 studies submitted to prospectively enroll patients with...
-
Apr 3, 2017
- Research conducted by Professor Paul Workman supports the use of SRA737 in certain genetically defined tumors and in combination with chemotherapy - VANCOUVER, April 3, 2017 /CNW/ - Sierra...
-
Mar 2, 2017
Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...
-
Feb 9, 2017
Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...
-
Feb 8, 2017
Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...